Table 7 Summary of studies measuring blood eosinophil % and absolute eosinophil count in CSU subjects
Reference (author, year) | Country | Definition of CSU in weeks | Treatment | Number of CSU patients undergoing eosinophil testing | Mean blood eosinophil % (SD) | Median blood eosinophil % (IQR) | Mean absolute eosinophil count | Median absolute eosinophil count (IQR) | Number of antihistamine (AH) and/or systemic corticosteroid (SC)-free days |
|---|---|---|---|---|---|---|---|---|---|
Toyoda, 1996 [113] | United States | – | None stated | 30 | – | – | 164.3 (SE 54.6) | – | 28 (SC) |
Di Lorenzo, 1996 [114] | Italy | > 8–12 | None stated | 13 | – | – | 270 (SD 90) | – | 2 (AH), SC not allowed |
Kim, 1997 [115] | Korea | – | None stated | 285 | – | – | 184.4 (SE 8.4) | – | 28 (SC) |
Grattan, 2003 [116] | United Kingdom | – | Loratadine & Prednisolone | 7 | – | – | 121 (SE 13) | – | 7 (AH), 28 (SC) |
Garmendia, 2004 [117] | Venezuela | > 6 | Ceterizine & Loratadine | 32 | – | – | 146 (SD 132) | – | 5 (AH), 3 (SC) |
Anuradha, 2010 [23] | India | > 6 | Loratadine | 30 | 4.1 (1.6) | – | 357 (SD 176) | – | 3 (AH), 28 (SC) |
Levocetirizine | 30 | 4.2 (1.4) | – | 368 (SD 131) | – | 3 (AH), 28 (SC) | |||
Boonpiyathad, 2014 [118] | Thailand | > 6 | Vitamin D | 60 | – | – | 127 (SD 50) | – | AH allowed |
Dakhale, 2014 [24] | India | > 6 | Cetirizine | 31 | 6.9 (1.9) | – | – | – | 7 (AH), 56 (SC) |
Rupatadine | 33 | 6.7 (1.5) | – | – | – | 7 (AH), 56 (SC) | |||
Woo, 2015 [119] | Korea | > 6 | None stated | 72 | 2.6 (1.8) | – | 202 (SD 239) | – | Not stated |
Dakhale, 2016 [50] | India | > 6 | Rupatadine | 30 | 6.9 (1.8) | – | – | – | 7 (AH), 56 (SC) |
Olopatadine | 30 | 6.8 (1.6) | – | – | – | 7 (AH), 56 (SC) | |||
Gomez-Vera, 2016 [25] | Mexico | > 6 | AH, Omalizumab | 76 | – | – | – | 170 (100–300) | Not allowed |
Wardhana, 2017 [120] | Bali | > 6 | None stated | 25 | – | – | 176 (SD 120) | – | Not stated |
Aitella, 2018 [121] | Italy | > 6 | None stated | 50 | – | – | 199 (SD 100) | 190 (110–268) | 7 (AH) |
Cildag, 2018 [122] | Turkey | > 6 | Omalizumab | 41 | – | – | – | 160 (80–245) | Not stated |
Türk, 2018 [87] | Turkey | > 6 | Omalizumab | 25 | – | 1.7 (0.9-2.8) | – | 130 (79–195) | AH, SC allowed |
Acer, 2019 [123] | Turkey | > 6 | Omalizumab | 106 | – | – | 150 (SD 170) | – | Not stated |
Akdogan, 2019 [124] | Turkey | > 6 | Omalizumab | 74 | 1.9 (1.9) | – | – | – | Not stated |
Kolkhir, 2019 [125] | Germany | > 6 | None stated | 1613 | – | – | – | 150 (80–230) | Allowed |
Nazik, 2019 [126] | Turkey | – | Omalizumab | 136 | 2.1 (2.0) | – | – | – | AH, SC allowed |
Oliver, 2019 [127] | United States | > 6 | None stated | 23 | 2.5 (0.4) | – | – | – | AH allowed, SC not allowed |
Tamer, 2020 [128] | Turkey | > 6 | Omalizumab | 60 | 2.5 (3.0) | – | 250 (SD 89) | – | SC not allowed |
Pediatrics studies | |||||||||
Jirapongsananuruk, 2010 [129] | Thailand | > 6 | None stated | 94 | – | – | 256 | – | 7 (AH) |
Chang, 2013 [26] | Taiwan | > 6 | None stated | 54 | – | 2.0 | – | – | Not stated |
Chansakulporn, 2014 [130] | Thailand | > 6 | None stated | 92 | – | – | – | 259 | 7 (AH) |
Cavkaytar, 2015 [131] | Turkey | > 6 | None stated | 68 | – | 1.4 (0.8–2.2) | – | 100 (100–200) | 8 (AH) |
Uysal, 2016 [132] | Turkey | > 6 | Desloratadine | 92 | – | – | – | 180 (80–290) | Allowed |
Lee, 2017 [133] | Korea | > 6 | None stated | 57 | 3.1 (1.6) | – | – | – | Not stated |